Evidence map›Paper›PMID 41901709›Full record

ArticlePathogens (Basel, Switzerland)2026

Ocular Syphilis in Individuals with and Without HIV: A Single-Center University Hospital Experience.

Murat Hakan Kır, Aysun Benli, Zarifa Orta, Seniha Başaran, Merih Oray, Halit Özsüt

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Murat Hakan KırDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34320, Türkiye.ORCID 0009-0004-9969-4061
Aysun BenliDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34320, Türkiye.ORCID 0000-0003-0679-0990
Zarifa OrtaDepartment of Infectious Diseases and Clinical Microbiology, Tekirdag Dr. Ismail Fehmi Cumalioglu City Hospital, Tekirdag 59030, Türkiye.ORCID 0000-0003-2028-7902
Seniha BaşaranDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34320, Türkiye.ORCID 0000-0002-3402-2510
Merih OrayDepartment of Ophthalmology, Faculty of Medicine, Yeni Yuzyil University, Istanbul 34010, Türkiye.ORCID 0000-0003-2830-6311
Halit ÖzsütDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34320, Türkiye.ORCID 0000-0002-5222-9320

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Syphilis is a re-emerging sexually transmitted infection with rising incidence worldwide, often associated with HIV infection. Ocular syphilis represents a severe manifestation that can occur at any disease stage and may result in permanent vision loss if not promptly diagnosed and treated. We conducted a retrospective comparative cohort study of 22 patients with ocular syphilis managed at Istanbul University, Istanbul Faculty of Medicine, between 2019 and 2025. Twelve patients (54.5%) were people living with HIV (PLWH). The majority were male (81.8%), with a mean age of 45.2 years. Visual loss was observed in more than half of the patients and occurred significantly more frequently in PLWH than in HIV-negative individuals (100% vs. 70%;

Indexed as

Eye Infections, BacterialHIV InfectionsSyphilisAdultAgedAnti-Bacterial AgentsFemaleHospitals, UniversityHumansMaleMiddle AgedNeurosyphilisRetrospective StudiesTurkeyUveitisAnti-Bacterial AgentsHIVneurosyphilisocular syphilisuveitisvisual loss

Identifiers

PMID41901709
PMCPMC13029101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.